Visit the Aurora Cannabis Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Barry Fishman Joins Aurora Board as Independent Director
Accomplished Pharma CEO and Cannabis Sector Director Further Strengthens Corporate Governance
VANCOUVER, Oct. 12, 2016 /CNW/ – Aurora Cannabis Inc. (TSXV: ACB) (FRANKFURT: 21P) (WKN: A1C4WM) (OTCQB: ACBFF) (the “Company” or “Aurora” or the “Issuer”) is pleased to announce the appointment of Barry Fishman to the Board of Directors.
Mr. Fishman, who will sit as an independent director, has a robust record of accomplishment as CEO of three major pharmaceutical companies, is a Certified Public Accountant (CPA), and has more than 30 years of experience in executive management, marketing and finance.
Mr. Fishman is the CEO of international specialty pharmaceutical company Merus Labs (TSX: MSL) (NASDAQ: MSLI), where he has led the company to more than tripling sales and EBITDA over the last two fiscal years. Previously, he has served as CEO of both Teva Canada and Taro Canada, and is a past Chair of the Canadian Generic Manufacturers Association. He began his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing. Mr. Fishman also has critical insights into the development of the cannabis sector, having previously served on the Board of Directors of Canopy Growth Corporation and Bedrocan Cannabis Corp.
“Barry is an outstanding addition to the Board, bringing extensive marketing, finance and capital markets experience, and further enhancing our corporate governance,” said Terry Booth, CEO. “His network and reputation, along with his wise judgment, will serve the Company and our shareholders well as we continue on our rapid growth trajectory, which includes expanding our production capacity, transitioning to profitable operations, and further establishing our leadership position in the Canadian cannabis industry.”
I am delighted to join Aurora, and to become part of this dynamic team that will continue to provide leadership and drive innovation in the cannabis sector. This Company has been a standout in terms of its rapid growth, management and Board strength, disciplined execution of its strategic plan, and vision for the future of the industry. I look forward to playing a key role in Aurora’s governance and strategic decision-making.
In connection with Mr. Fishman’s appointment as a Director, the Company granted him stock options to acquire 350,000 common shares in the capital of the Company, exercisable at $2.38 per share, expiring in five years. These options will vest evenly on a quarterly basis over a period of one year.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the TSX Venture Exchange under the symbol “ACB”.
For fact-based information on Aurora Cannabis, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.